
The third-quarter financials of Danish medical technology firm Ambu ended up slightly better than expected earlier this year after the company presented preliminary figures in connection with a downgrade.
Ambu now reports that its revenue has come to just above the DKK 971m (USD 153.6m) announced in July, and the DKK 62m bottom line is well above the DKK 49m forecast by analysts.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app